Company Overview of Lycera Corp.
Lycera Corp., a biopharmaceutical company, discovers and develops oral immune modulators for the treatment of patients with autoimmune diseases and cancers. Its product pipeline includes LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease; oral RORgamma agonists for diverse applications in immune-oncology; and Rho kinase inhibitors, histone deacetylase 6 inhibitors, RORgt antagonists, and collaboration targets. Lycera Corp. was founded in 2006 and is headquartered in Ann Arbor, Michigan.
2800 Plymouth Road
Ann Arbor, MI 48109
Founded in 2006
Key Executives for Lycera Corp.
Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Director
Senior Vice President of Corporate Development and Strategy
Compensation as of Fiscal Year 2015.
Lycera Corp. Key Developments
Lycera Corp. Presents at Boston Biotech Conferences 2015, Nov-12-2015 02:00 PM
Nov 8 15
Lycera Corp. Presents at Boston Biotech Conferences 2015, Nov-12-2015 02:00 PM. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States.
Lycera Corp Appoints Alex G. Howarth as Chief Financial Officer
Oct 6 15
Lycera Corp. announced the appointment of Alex G. Howarth as Chief Financial Officer. With over 25 years of experience in healthcare and financial advisory roles, Mr. Howarth brings to Lycera a distinguished track record in the industry. He will be responsible for all finance-related activities for the Company, including accounting, financial planning, and strategic analysis. Mr. Howarth will report directly to Paul Sekhri, Lycera's President and CEO, and his appointment is effective immediately. Prior to joining Lycera Corp., Mr. Howarth most recently served as Executive Vice President and Chief Financial Officer of moksha8.
Lycera and Celgene Partner to Advance Development of Immune Modulators
Jun 10 15
Lycera has entered an exclusive strategic collaboration with Celgene to advance the development of its proprietary pipeline for cancer and immune-mediated diseases. The partnership will advance development of Lycera's novel pipeline, including first-in-class RORgamma agonists for cancer immunotherapy and clinical-stage candidate, LYC-30937, being studied for inflammatory bowel disease (IBD). As part of the deal, Lycera will provide an $82.5 million upfront cash payment, which comprises an exclusive option for Celgene to license Lycera's portfolio of ex-vivo RORgamma agonist compounds. The deal will also allow Lycera to receive near term payments of an additional $22.5 million associated with the ex-vivo licensing option rights. In addition, the deal provides Celgene exclusive rights to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 12, 2015